The investment in the plant is part of an HPAI expansion strategy started in 1996 to meet growing demand for low dose, highly selective active ingredients.
The new HPAI plant offers cGMP preparative chromatography on the second floor; synthesis, drying and isolation on the first floor; with a warehouse, dispensing and repackaging on the ground floor.
The sophisticated technologies installed in the plant allow the production of active ingredients in low dosages using containment units that fully protect the operator (OEL < 50 nanograms) and the environment during synthesis and manipulation of the resulting dust. Also included is a new system for a dedicated multi-purpose plant.
There is additional space to add more production units or other technologies under development for optimising yield, time and costs, the company says.
Cerbios-Pharma has made a series of investments at the plant since 1999 and has increased turnover and profitability, as well as expanding the workforce by 56%. Further expansion is planned, which will create additional jobs in the Ticino region.
